Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.81
+0.65007.10%
Post-market: 9.69-0.1200-1.22%19:55 EDT
Volume:9.24M
Turnover:88.43M
Market Cap:2.46B
PE:8.11
High:9.98
Open:9.15
Low:9.05
Close:9.16
52wk High:11.31
52wk Low:6.00
Shares:250.80M
Float Shares:218.00M
Volume Ratio:1.15
T/O Rate:4.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:587.33%
ROA:43.21%
PB:-20.65
PE(LYR):8.11

Loading ...

BioCryst Pharmaceuticals Inc - Increases Orladeyo Price to $48,487.92 per 28-Day Pack - SEC Filing

THOMSON REUTERS
·
Jan 09

RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating

MT Newswires Live
·
Jan 08

BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says

MT Newswires Live
·
Dec 30, 2025

Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals

Reuters
·
Dec 24, 2025

BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares

Reuters
·
Dec 24, 2025

BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

BioCryst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 15, 2025

BioCryst Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $32 From $30

THOMSON REUTERS
·
Dec 15, 2025

BioCryst Pharmaceuticals Shares Reverse Premarket Course, Last Down 1%

THOMSON REUTERS
·
Dec 12, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Dec 12, 2025

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears

MT Newswires Live
·
Dec 12, 2025

BioCryst Pharmaceuticals Shares up 2.9% Premarket After FDA Nod of Rare Disease Drug for Children

THOMSON REUTERS
·
Dec 12, 2025

FDA expands approval of BioCryst's rare disease drug for use in young children

Reuters
·
Dec 12, 2025

FDA Approves BioCryst's ORLADEYO Oral Pellets for Pediatric HAE Prevention

Reuters
·
Dec 12, 2025

BioCryst Announces FDA Approval of Orladeyo® (Berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients With Hae Aged 2 to <12 Years

THOMSON REUTERS
·
Dec 12, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:41 AM

Reuters
·
Dec 12, 2025

BioCryst Pharmaceuticals Inc - on Dec 9, Vincent J. Milano Elected as Next Chair of Board - SEC Filing

THOMSON REUTERS
·
Dec 11, 2025

Vincent J. Milano Named Next Chair of BioCryst Pharmaceuticals Board

Reuters
·
Dec 11, 2025

BioCryst Grants New Hires Stock Options and RSUs as Inducement

Reuters
·
Dec 04, 2025

BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025